Foretellix Unveils Reference Solution Integrating NVIDIA Alpamayo to Scale AI Autonomous Vehicle Development

Foretellix Unveils Reference Solution Integrating NVIDIA Alpamayo to Scale AI Autonomous Vehicle Development

SUNNYVALE, Calif., June 1, 2026 /PRNewswire/ -- Foretellix, provider of safety and data infrastructure for physical AI, today announced its Reference Solution for the NVIDIA Alpamayo ecosystem. Foretellix enables developers building AI-powered...

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC

NANJING, China, May 28, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig...

AION UT Global Launch Drives Strong Sales Across Key Markets and Multiple International Honors

AION UT Global Launch Drives Strong Sales Across Key Markets and Multiple International Honors

GUANGZHOU, China, May 27, 2026 /PRNewswire/ -- Since its 2025 global debut, the AION UT has rapidly gained traction across Southeast Asia, South America, and Europe. In Q1, it delivered over 2,400 units in Thailand—securing a Top 3 position in the...

Neurovia AI, a Subsidiary of Robo.ai, Concludes Participation at ISNR2026, Demonstrating NeuroStream™ Visual Data Infrastructure and 96.37% Visually Lossless Compression

Neurovia AI, a Subsidiary of Robo.ai, Concludes Participation at ISNR2026, Demonstrating NeuroStream™ Visual Data Infrastructure and 96.37% Visually Lossless Compression

ABU DHABI, UAE, May 21, 2026 /PRNewswire/ -- Neurovia AI, an artificial intelligence data processing and compression technology provider and a subsidiary of Robo.ai Inc. (NASDAQ: AIIO), announced the conclusion of its inaugural presentation at the...

UN Global Compact Africa Business Leaders Coalition Unveils New Roadmap to Accelerate Intra-African Trade and Sustainable Growth

UN Global Compact Africa Business Leaders Coalition Unveils New Roadmap to Accelerate Intra-African Trade and Sustainable Growth

KIGALI, Rwanda, May 16, 2026 /PRNewswire/ -- The Africa Business Leaders Coalition (ABLC), a CEO-led platform convened by the UN Global Compact to bring together leading African CEOs and companies to advance sustainable growth, climate action,...

Hyundai Motor Reaffirms China Commitment at Auto China 2026, Unveils IONIQ V as First Step in New Product Offensive

Hyundai Motor Reaffirms China Commitment at Auto China 2026, Unveils IONIQ V as First Step in New Product Offensive

Hyundai Motor advances a renewed China strategy anchored in its 'In China, For China, To Global' approach IONIQ V debuts as the first dedicated IONIQ production model for China, tailored to local customer needs and expectations China positioned as a...

CloudMile Sweeps Four Major Awards at Google Cloud Next 2026 Demonstrating Cloud Technology Leadership in APAC

CloudMile Sweeps Four Major Awards at Google Cloud Next 2026 Demonstrating Cloud Technology Leadership in APAC

CloudMile is honored to receive four APAC awards at Google Cloud Next 2026. Building on momentum since 2024, CloudMile remains dedicated to delivering excellence in data and cloud leadership across the region. SINGAPORE, April 22, 2026 /PRNewswire/...

Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain

Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain

— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker reductions — — Preliminary data from 180 mg cohort shows trends of clinical stabilization (ALSFRS-R) — — Phase II trial is now...

Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile

Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile

– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23% – No Grade 3 or higher adverse events related to RZ-001 observed – Highlights clinical potential of RNA...

Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026

Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026

SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent...

  • 1
  • 2
  • 3
  • menu
    menu